Biosyent Inc logo

RX - Biosyent Inc News Story

C$7.9 0.3  4.0%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £59.1m
Enterprise Value £45.3m
Revenue £12.9m
Position in Universe 860th / 2713

BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020

Tue 17th November, 2020 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201117:nGNX3R8s5k


MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc.
(“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its
financial results for the three and nine months ended September 30, 2020 on
Thursday, November 26, 2020. A presentation on the Company’s third quarter
and year-to-date 2020 results by René Goehrum, BioSyent President and CEO,
will also be available on the Company’s website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent
is a profitable growth-oriented specialty pharmaceutical company focused on
in-licensing or acquiring innovative pharmaceutical and other healthcare
products that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients. BioSyent
supports the healthcare professionals that treat these patients by marketing
its products through its community, specialty/hospital and international
business units.

As of the date of this press release, the Company has 12,808,600 common shares
outstanding.

For a direct market quote for the TSX Venture Exchange and other Company
financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/3dded277-7953-4418-be63-7d7a3067811d)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.